Edition:
United States

Becton Dickinson and Co (BDX)

BDX on New York Consolidated

193.20USD
25 Sep 2017
Change (% chg)

$0.14 (+0.07%)
Prev Close
$193.06
Open
$192.91
Day's High
$193.62
Day's Low
$192.04
Volume
1,198,324
Avg. Vol
1,279,219
52-wk High
$206.63
52-wk Low
$161.29

Select another date:

Tue, Sep 12 2017

BRIEF-Becton Dickinson and Co announces launch of platform for RNA expression analysis

* Becton Dickinson and Co - announces launch of BD rhapsody, a platform for RNA expression analysis

BRIEF-BD announces extension of exchange offers and consent solicitations for C. R. Bard Inc notes

* BD announces extension of exchange offers and consent solicitations for C. R. Bard Inc notes

BRIEF-Retractable Technologies says court dismissed co's case against Becton, Dickinson and Co​

* On August 17, judge issued court's final judgment regarding RTI's suit against Becton, Dickinson and Co​

FDA probes possible Becton Dickinson link to faulty lead tests (Aug. 17)

(The August 17 story has been updated with a correct headline and first paragraph to show the FDA is still investigating blood tubes from Becton Dickinson and the tubes have not been ruled out yet)

CORRECTED-FDA probes possible Becton Dickinson link to faulty lead tests (Aug. 17)

Aug 17 Blood collection tubes made by Becton Dickinson & Co that were used in conjunction with Magellan Diagnostics' lead-testing devices are still being investigated as a potential cause of inaccurate lead test results.

BRIEF-FDA provides update on its investigation into inaccurate results from certain lead tests‍​

* U.S. FDA provides update on its investigation into inaccurate results from certain lead tests‍​

BRIEF-C.R. Bard shareholders approve proposed merger with Becton Dickinson

* Bard shareholders approve proposed merger with becton, dickinson

BRIEF-Becton Dickinson and Co reports Q3 loss per share $0.75

* Q3 revenue $3.035 billion versus I/B/E/s view $3.06 billion

BRIEF-Becton Dickinson extends exchange for C. R. Bard, Inc. notes

* BD announces extension of exchange offers and consent solicitations for C. R. Bard, Inc. Notes

BRIEF-BD receives FDA clearance for new immunological diagnostic system

* BD receives FDA 510(k) clearance for new immunological diagnostic system Source text for Eikon: Further company coverage:

Select another date: